• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Computer Methods and Programs in Biomedicine: An International Journal Devoted to the Development, Implementation and Exchange of Computing Methodology and Software Systems in Biomedical Research and Medical Practice >An intelligent decision support algorithm for diagnosis of colorectal cancer through serum tumor markers.
【24h】

An intelligent decision support algorithm for diagnosis of colorectal cancer through serum tumor markers.

机译：通过血清肿瘤标志物诊断大肠癌的智能决策支持算法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nowadays, a wide range of serum tumor markers can be applied in the diagnosis of colorectal cancer. There exists a wide variability in the type and number of routinely used markers so that, sometimes, patients may receive redundant or insufficient checks. Furthermore, the traditional single cutoff point also hinders the efficient utilization of the continuous check value of a tumor marker. In order to improve the diagnostic accuracy (DA) and decrease the cost, it is necessary to optimize the check combinations and exploit the check values fully. To this end, focusing on colorectal cancer (CRC), an artificial intelligent algorithm entitled DS-STM (diagnosis strategy of serum tumor makers) is developed in this paper. DS-STM can provide decision support for physicians on the usage of different tumor markers and diagnosis of colorectal cancer (CRC). The study demonstrates that, instead of five or more tumor markers, two markers are already enough for diagnosis for most CRC patients. The experimental study shows, compared to the traditional serial test, DS-STM can improve DA from 67.53% to 73.87% for the same validation dataset. In addition, a significant cost reduction can be achieved with the new developed diagnosis strategy.
机译：如今，广泛的血清肿瘤标志物可用于大肠癌的诊断。常规使用的标记的类型和数量存在很大的差异，因此有时患者可能会收到多余或不足的检查。此外，传统的单一截止点也阻碍了肿瘤标志物的连续检查值的有效利用。为了提高诊断准确性（DA）和降低成本，有必要优化检查组合并充分利用检查值。为此，本文针对结直肠癌（CRC），开发了一种名为DS-STM（血清肿瘤产生者的诊断策略）的人工智能算法。 DS-STM可以为医生提供有关不同肿瘤标记物的使用和大肠癌（CRC）诊断的决策支持。该研究表明，对于大多数CRC患者而言，已经有两个标志物足以代替5个或更多个肿瘤标志物进行诊断。实验研究表明，与传统的串行测试相比，对于相同的验证数据集，DS-STM可以将DA从67.53％提高到73.87％。此外，新开发的诊断策略可以显着降低成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号